

# Parkinson's disease in over 20s: diagnosis and management

Clinical guideline

Published: 28 June 2006

[nice.org.uk/guidance/cg35](https://www.nice.org.uk/guidance/cg35)

## Contents

Introduction .....	4
Patient-centred care .....	5
Key priorities for implementation .....	6
1 Guidance .....	9
1.1 Communication with people with Parkinson's disease and their carers .....	9
1.2 Diagnosing Parkinson's disease .....	10
1.3 Neuroprotection .....	11
1.4 Pharmacological therapy in early PD .....	12
1.5 Pharmacological therapy in later PD .....	14
1.6 Further drug administration considerations .....	17
1.7 Surgery for Parkinson's disease .....	17
1.8 Non-motor features of Parkinson's disease .....	18
1.9 Other key interventions .....	21
1.10 Palliative care in Parkinson's disease .....	23
2 Notes on the scope of the guidance .....	24
3 Implementation in the NHS .....	25
4 Research recommendations .....	26
4.1 Neuroprotection .....	26
4.2 Dementia .....	26
4.3 Depression .....	27
4.4 Supportive therapies .....	28
4.5 Diagnostic investigations .....	29
5 Other versions of this guideline .....	31
5.1 Full guideline .....	31
5.2 Information for the public .....	31
6 Related NICE guidance .....	32
7 Review date .....	33

Appendix A: Grading scheme .....	34
Appendix B: The Guideline Development Group .....	35
Appendix C: The Guideline Review Panel .....	38
Appendix D: Technical detail on the criteria for audit .....	39
Appendix E: Algorithm .....	41
About this guideline .....	42

This guideline should be read in conjunction with IPG19.

## Introduction

Parkinson's disease (PD) is a progressive neurodegenerative condition resulting from the death of the dopamine-containing cells of the substantia nigra. There is no consistently reliable test that can distinguish PD from other conditions that have similar clinical presentations. The diagnosis is primarily clinical, based on a history and examination.

People with PD classically present with the symptoms and signs associated with parkinsonism, namely bradykinesia, rigidity and rest tremor.

Parkinsonism can also be caused by drugs, and conditions that are less common than PD. These include multiple cerebral infarction and degenerative conditions such as progressive supra-nuclear palsy (PSP) and multiple system atrophy (MSA).

Although PD is predominantly a movement disorder, other impairments frequently develop including psychiatric problems such as depression and dementia. Autonomic disturbances and pain (which is rarely a presenting feature of PD) may later ensue, and the condition progresses to cause significant disability and handicap with impaired quality of life for the affected person. Family and carers may also be affected indirectly.

### Health and resource implications

PD is a common, chronic, progressive neurological condition, estimated to affect 100–180 people per 100,000 of the population (between 6 and 11 people per 6000 of the general population in the UK)<sup>[1]</sup> and has an annual incidence of 4–20 per 100,000. There is a rising prevalence with age and a higher prevalence and incidence of PD in males.

The recommendations in this guideline were graded according to the quality of the evidence they were based on. The gradings are available in the [NICE guideline](#) and are not shown in this web version.

---

<sup>[1]</sup> The size of the average general practice list in the UK.

## Patient-centred care

This guideline offers best practice advice on the care of people with PD and should be read in conjunction with the [national service framework \(NSF\) for long-term \(neurological\) conditions \(2005\)](#).

Treatment and care should take into account patients' individual needs and preferences. People with PD should have the opportunity to make informed decisions about their care and treatment. Where patients do not have the capacity to make decisions, healthcare professionals should follow the [Department of Health's advice on consent](#) and the [code of practice that accompanies the Mental Capacity Act](#). In Wales, healthcare professionals should follow [advice on consent from the Welsh Government](#).

Good communication between healthcare professionals and patients is essential. It should be supported by the provision of evidence-based information offered in a form that is tailored to the needs of the individual patient. The treatment, care and information provided should be culturally appropriate and in a form that is accessible to people who have additional needs, such as people with physical, cognitive or sensory disabilities, and people who do not speak or read English.

Unless specifically excluded by the patient, carers and relatives should have the opportunity to be involved in decisions about the person's care and treatment.

Carers and relatives should also be provided with the information and support they need.

## Key priorities for implementation

The following recommendations have been identified as priorities for implementation.

### Referral to expert for accurate diagnosis

- People with suspected PD should be referred quickly<sup>[2]</sup> and untreated to a specialist with expertise in the differential diagnosis of this condition.

### Diagnosis and expert review

- The diagnosis of PD should be reviewed regularly<sup>[3]</sup> and reconsidered if atypical clinical features develop.
- Acute levodopa and apomorphine challenge tests should not be used in the differential diagnosis of parkinsonian syndromes.

### Regular access to specialist nursing care

- People with PD should have regular access to the following:
  - clinical monitoring and medication adjustment
  - a continuing point of contact for support, including home visits, when appropriate
  - a reliable source of information about clinical and social matters of concern to people with PD and their carers

which may be provided by a Parkinson's disease nurse specialist.

### Access to physiotherapy

- Physiotherapy should be available for people with PD. Particular consideration should be given to:
  - gait re-education, improvement of balance and flexibility
  - enhancement of aerobic capacity
  - improvement of movement initiation
  - improvement of functional independence, including mobility and activities of daily living

- provision of advice regarding safety in the home environment.

### Access to occupational therapy

- Occupational therapy should be available for people with PD. Particular consideration should be given to:
  - maintenance of work and family roles, employment, home care and leisure activities
  - improvement and maintenance of transfers and mobility
  - improvement of personal self-care activities, such as eating, drinking, washing and dressing
  - environmental issues to improve safety and motor function
  - cognitive assessment and appropriate intervention.

### Access to speech and language therapy

- Speech and language therapy should be available for people with PD. Particular consideration should be given to:
  - improvement of vocal loudness and pitch range, including speech therapy programmes such as Lee Silverman Voice Treatment (LSVT)
  - teaching strategies to optimise speech intelligibility
  - ensuring an effective means of communication is maintained throughout the course of the disease, including use of assistive technologies
  - review and management to support the safety and efficiency of swallowing and to minimise the risk of aspiration.

### Palliative care

- Palliative care requirements of people with PD should be considered throughout all phases of the disease.
  - People with PD and their carers should be given the opportunity to discuss end-of-life issues with appropriate healthcare professionals.
-

<sup>[2]</sup> The Guideline Development Group considered that people with suspected mild PD should be seen within 6 weeks but new referrals in later disease with more complex problems require an appointment within 2 weeks.

<sup>[3]</sup> The Guideline Development Group considered that people diagnosed with PD should be seen at regular intervals of 6–12 months to review their diagnosis.

## 1 Guidance

### 1.1 *Communication with people with Parkinson's disease and their carers*

#### 1.1.1 Communication

- 1.1.1.1 Communication with people with PD should be aimed towards empowering them to participate in the judgements and choices about their own care.
- 1.1.1.2 Discussions should be aimed at achieving a balance between the provision of honest realistic information about the condition and the promotion of a feeling of optimism.
- 1.1.1.3 Because people with PD may develop impaired cognitive ability, a communication deficit and/or depression, they should be provided with:
- both oral and written communication throughout the course of the disease, which should be individually tailored and reinforced as necessary
  - consistent communication from the professionals involved.
- 1.1.1.4 Families and carers should be given information about the condition, their entitlements to care assessment and the support services available.
- 1.1.1.5 People with PD should have a comprehensive care plan agreed between the individual, their family and/or carers and specialist and secondary healthcare providers.
- 1.1.1.6 People with PD should be offered an accessible point of contact with specialist services. This could be provided by a Parkinson's disease nurse specialist.
- 1.1.1.7 All people with PD who drive should be advised to inform the Driver and Vehicle Licensing Agency (DVLA) and their car insurer of their condition at the time of diagnosis.

## **1.2 Diagnosing Parkinson's disease**

### **1.2.1 Definition and differential diagnosis**

1.2.1.1 PD should be suspected in people presenting with tremor, stiffness, slowness, balance problems and/or gait disorders.

### **1.2.2 Expert versus non-expert diagnosis**

1.2.2.1 People with suspected PD should be referred quickly<sup>[4]</sup> and untreated to a specialist with expertise in the differential diagnosis of this condition.

### **1.2.3 Clinical versus post-mortem diagnosis**

1.2.3.1 PD should be diagnosed clinically and based on the UK Parkinson's Disease Society Brain Bank Criteria.

1.2.3.2 Clinicians should be encouraged to discuss with patients the possibility of tissue donation to a brain bank for purposes of diagnostic confirmation and research.

### **1.2.4 Review of diagnosis**

1.2.4.1 The diagnosis of PD should be reviewed regularly<sup>[5]</sup> and re-considered if atypical clinical features develop.

### **1.2.5 Single photon emission computed tomography (SPECT)**

1.2.5.1 <sup>123</sup>I-FP-CIT SPECT should be considered for people with tremor where essential tremor cannot be clinically differentiated from parkinsonism.

1.2.5.2 <sup>123</sup>I-FP-CIT SPECT should be available to specialists with expertise in its use and interpretation.

### **1.2.6 Positron emission tomography (PET)**

1.2.6.1 PET should not be used in the differential diagnosis of parkinsonian syndromes, except in the context of clinical trials.

## **1.2.7 Structural magnetic resonance imaging (MRI)**

1.2.7.1 Structural MRI should not be used in the differential diagnosis of Parkinson's disease.

1.2.7.2 Structural MRI may be considered for the differential diagnosis of parkinsonian syndromes.

## **1.2.8 Magnetic resonance volumetry**

1.2.8.1 Magnetic resonance volumetry should not be used in the differential diagnosis of parkinsonian syndromes, except in the context of clinical trials.

## **1.2.9 Magnetic resonance spectroscopy**

1.2.9.1 Magnetic resonance spectroscopy should not be used in the differential diagnosis of parkinsonian syndromes.

## **1.2.10 Acute levodopa and apomorphine challenge tests**

1.2.10.1 Acute levodopa and apomorphine challenge tests should not be used in the differential diagnosis of parkinsonian syndromes.

## **1.2.11 Objective smell testing**

1.2.11.1 Objective smell testing should not be used in the differential diagnosis of parkinsonian syndromes, except in the context of clinical trials.

## **1.3 *Neuroprotection***

### **1.3.1 Vitamin E**

1.3.1.1 Vitamin E should not be used as a neuroprotective therapy for people with PD.

### **1.3.2 Co-enzyme Q<sub>10</sub>**

1.3.2.1 Co-enzyme Q<sub>10</sub> should not be used as a neuroprotective therapy for people with PD, except in the context of clinical trials.

### 1.3.3 Dopamine agonists

1.3.3.1 Dopamine agonists should not be used as neuroprotective therapies for people with PD, except in the context of clinical trials.

### 1.3.4 Monoamine oxidase B inhibitors

1.3.4.1 Monoamine oxidase B (MAO-B) inhibitors should not be used as neuroprotective therapies for people with PD, except in the context of clinical trials.

## 1.4 *Pharmacological therapy in early PD*

In this guideline, 'early disease' refers to PD in people who have developed functional disability and require symptomatic therapy. 'Later disease' refers to PD in people on levodopa who have developed motor complications.

### 1.4.1 Choice of initial pharmacotherapy in people with early PD

There is no single drug of choice in the initial pharmacotherapy of early PD. Table 1 may help to guide the reader through the following section.

**Table 1 Options for initial pharmacotherapy in early PD**

Initial therapy for early PD	First-choice option	Symptom control	Risk of side effects	
			Motor complications	Other adverse events
Levodopa	Yes	Good degree of symptom control	Evidence of increased motor complications	Evidence of increased other adverse events
Dopamine agonists	Yes	Moderate degree of symptom control	Evidence of reduced motor complications	Evidence of increased other adverse events
MAO-B inhibitors	Yes	Limited degree of symptom control	Evidence of reduced motor complications	Evidence of increased other adverse events
Anticholinergics	No	Lack of evidence	Lack of evidence	Lack of evidence

Beta-blockers	No	Lack of evidence	Lack of evidence	Lack of evidence
Amantadine	No	Lack of evidence	Lack of evidence	Lack of evidence

1.4.1.1 It is not possible to identify a universal first-choice drug therapy for people with early PD. The choice of drug first prescribed should take into account:

- clinical and lifestyle characteristics
- patient preference, after the patient has been informed of the short- and long-term benefits and drawbacks of the drug classes.

## 1.4.2 Levodopa

1.4.2.1 Levodopa may be used as a symptomatic treatment for people with early PD.

1.4.2.2 The dose of levodopa should be kept as low as possible to maintain good function in order to reduce the development of motor complications.

## 1.4.3 Dopamine agonists

1.4.3.1 Dopamine agonists may be used as a symptomatic treatment for people with early PD.

1.4.3.2 A dopamine agonist should be titrated to a clinically efficacious dose. If side effects prevent this, another agonist or a drug from another class should be used in its place.

1.4.3.3 If an ergot-derived dopamine agonist is used, the patient should have a minimum of renal function tests, erythrocyte sedimentation rate (ESR) and chest radiograph performed before starting treatment, and annually thereafter.<sup>[6]</sup>

1.4.3.4 In view of the monitoring required with ergot-derived dopamine agonists, a non-ergot-derived agonist should be preferred in most cases.

## 1.4.4 Monoamine oxidase B inhibitors

1.4.4.1 MAO-B inhibitors may be used as a symptomatic treatment for people with early PD.

## 1.4.5 Beta-adrenergic antagonists (beta-blockers)

1.4.5.1 Beta-adrenergic antagonists may be used in the symptomatic treatment of selected people with postural tremor in PD, but should not be drugs of first choice.

## 1.4.6 Amantadine

1.4.6.1 Amantadine may be used as a treatment for people with early PD but should not be a drug of first choice.

## 1.4.7 Anticholinergics

1.4.7.1 Anticholinergics may be used as a symptomatic treatment typically in young people with early PD and severe tremor, but should not be drugs of first choice due to limited efficacy and the propensity to cause neuropsychiatric side effects.

## 1.4.8 Modified-release levodopa

1.4.8.1 Modified-release levodopa preparations should not be used to delay the onset of motor complications in people with early PD.

## 1.5 *Pharmacological therapy in later PD*

Most people with PD will develop, with time, motor complications and will eventually require levodopa therapy. Adjuvant drugs to take alongside levodopa have been developed with the aim of reducing these motor complications and improving quality of life.

### 1.5.1 Choice of adjuvant therapy for people with later PD

There is no single drug of choice in the pharmacotherapy of later PD. Table 2 may help to guide the reader through the following section.

Table 2 Options for adjuvant pharmacotherapy in later PD

Adjuvant therapy for later PD	First-choice option	Symptom control	Risk of side effects	
			Motor complications	Other adverse events

Dopamine agonists	Yes	Moderate degree of symptom control	Evidence of reduced motor complications	Evidence of increased other adverse events
COMT inhibitors	Yes	Moderate degree of symptom control	Evidence of reduced motor complications	Evidence of increased other adverse events
MAO-B inhibitors	Yes	Moderate degree of symptom control	Evidence of reduced motor complications	Evidence of increased other adverse events
Amantadine	No	Non-significant result	Evidence of reduced motor complications	Evidence of increased other adverse events
Apomorphine	No	Limited degree of symptom control	Evidence of reduced motor complications	Evidence of increased other adverse events

1.5.1.1 It is not possible to identify a universal first-choice adjuvant drug therapy for people with later PD. The choice of adjuvant drug first prescribed should take into account:

- clinical and lifestyle characteristics
- patient preference, after the patient has been informed of the short- and long-term benefits and drawbacks of the drug classes.

## 1.5.2 Modified-release levodopa

1.5.2.1 Modified-release levodopa preparations may be used to reduce motor complications in people with later PD, but should not be drugs of first choice.

## 1.5.3 Dopamine agonists

1.5.3.1 Dopamine agonists may be used to reduce motor fluctuations in people with later PD.

1.5.3.2 If an ergot-derived dopamine agonist is used, the patient should have a minimum of renal function tests, erythrocyte sedimentation rate (ESR) and chest radiograph performed before starting treatment, and annually thereafter<sup>[6]</sup>.

1.5.3.3 A dopamine agonist should be titrated to a clinically efficacious dose. If side effects prevent this, then another agonist or a drug from another class should be used in its place.

1.5.3.4 In view of the monitoring required with ergot-derived dopamine agonists, a non-ergot-derived agonist should be preferred, in most cases.

## 1.5.4 Monoamine oxidase B inhibitors

1.5.4.1 MAO-B inhibitors may be used to reduce motor fluctuations in people with later PD.

## 1.5.5 Catechol-O-methyl transferase inhibitors

1.5.5.1 Catechol-O-methyl transferase (COMT) inhibitors may be used to reduce motor fluctuations in people with later PD.

1.5.5.2 In view of problems with reduced concordance, people with later PD taking entacapone should be offered a triple combination preparation of levodopa, carbidopa and entacapone<sup>[7]</sup>.

1.5.5.3 Tolcapone should only be used after entacapone has failed in people with later PD due to lack of efficacy or side effects. Liver function tests are required every 2 weeks during the first year of therapy, and thereafter in accordance with the 'Summary of product characteristics'.

## 1.5.6 Amantadine

1.5.6.1 Amantadine may be used to reduce dyskinesia in people with later PD.

## 1.5.7 Apomorphine

1.5.7.1 Intermittent apomorphine injections may be used to reduce off time in people with PD with severe motor complications.

1.5.7.2 Continuous subcutaneous infusions of apomorphine may be used to reduce off time and dyskinesia in people with PD with severe motor complications. Its initiation should be restricted to expert units with facilities for appropriate monitoring.

## 1.6 *Further drug administration considerations*

- 1.6.1.1 Antiparkinsonian medication should not be withdrawn abruptly or allowed to fail suddenly due to poor absorption (for example, gastroenteritis, abdominal surgery) to avoid the potential for acute akinesia or neuroleptic malignant syndrome.
- 1.6.1.2 The practice of withdrawing patients from their antiparkinsonian drugs (so called 'drug holidays') to reduce motor complications should not be undertaken because of the risk of neuroleptic malignant syndrome.
- 1.6.1.3 In view of the risks of sudden changes in antiparkinsonian medication, people with PD who are admitted to hospital or care homes should have their medication:
- given at the appropriate times, which in some cases may mean allowing self-medication.
  - adjusted by, or adjusted only after discussion with, a specialist in the management of PD.
- 1.6.1.4 Clinicians should be aware of dopamine dysregulation syndrome, an uncommon disorder in which dopaminergic medication misuse is associated with abnormal behaviours, including hypersexuality, pathological gambling and stereotypic motor acts. This syndrome may be difficult to manage.

## 1.7 *Surgery for Parkinson's disease*

NICE has also published interventional procedure guidance [Deep brain stimulation for Parkinson's disease](#).

### 1.7.1 **Subthalamic nucleus stimulation**

- 1.7.1.1 Bilateral subthalamic nucleus (STN) stimulation may be used in people with PD who:
- have motor complications that are refractory to best medical treatment,
  - are biologically fit with no clinically significant active comorbidity,

- are levodopa responsive and
- have no clinically significant active mental health problems, for example, depression or dementia.

## 1.7.2 Globus pallidus interna stimulation

1.7.2.1 Bilateral globus pallidus interna (GPI) stimulation<sup>[8]</sup> may be used in people with PD who:

- have motor complications that are refractory to best medical treatment,
- are biologically fit with no clinically significant active comorbidity,
- are levodopa responsive and
- have no clinically significant active mental health problems, for example, depression or dementia.

## 1.7.3 Comparison of STN and GPI stimulation

1.7.3.1 With the current evidence it is not possible to decide if the subthalamic nucleus or globus pallidus interna is the preferred target for deep brain stimulation for people with PD, or whether one form of surgery is more effective or safer than the other. In considering the type of surgery, account should be taken of:

- clinical and lifestyle characteristics of the person with PD
- patient preference, after the patient has been being informed of the potential benefits and drawbacks of the different surgical procedures.

## 1.7.4 Thalamic stimulation

1.7.4.1 Thalamic deep brain stimulation may be considered as an option in people with PD who predominantly have severe disabling tremor and where STN stimulation cannot be performed.

## 1.8 *Non-motor features of Parkinson's disease*

### 1.8.1 Mental health problems

#### Depression

- 1.8.1.1 Clinicians should have a low threshold for diagnosing depression in PD.
- 1.8.1.2 Clinicians should be aware that there are difficulties in diagnosing mild depression in people with PD because the clinical features of depression overlap with the motor features of PD.
- 1.8.1.3 The management of depression in people with PD should be tailored to the individual, in particular, to their co-existing therapy.

### Psychotic symptoms

- 1.8.1.4 All people with PD and psychosis should receive a general medical evaluation and treatment for any precipitating condition.
- 1.8.1.5 Consideration should be given to withdrawing gradually antiparkinsonian medication that might have triggered psychosis in people with PD.
- 1.8.1.6 Mild psychotic symptoms in people with PD may not need to be actively treated if they are well tolerated by the patient and carer.
- 1.8.1.7 Typical antipsychotic drugs (such as phenothiazines and butyrophenones) should not be used in people with PD because they exacerbate the motor features of the condition.
- 1.8.1.8 Atypical antipsychotics may be considered for treatment of psychotic symptoms in people with PD, although the evidence base for their efficacy and safety is limited.
- 1.8.1.9 Clozapine may be used in the treatment of psychotic symptoms in PD, but registration with a mandatory monitoring scheme is required. It is recognised that few specialists caring for people with PD have experience with clozapine.

### Dementia

- 1.8.1.10 Although cholinesterase inhibitors have been used successfully in individual people with PD dementia, further research is recommended to identify those patients who will benefit from this treatment.

## 1.8.2 Sleep disturbance

- 1.8.2.1 A full sleep history should be taken from people with PD who report sleep disturbance.
- 1.8.2.2 Good sleep hygiene should be advised in people with PD with any sleep disturbance and includes:
- avoidance of stimulants (for example, coffee, tea, caffeine) in the evening
  - establishment of a regular pattern of sleep
  - comfortable bedding and temperature
  - provision of assistive devices, such as a bed lever or rails to aid with moving and turning, allowing the person to get more comfortable
  - restriction of daytime siestas
  - advice about taking regular and appropriate exercise to induce better sleep
  - a review of all medication and avoidance of any drugs that may affect sleep or alertness, or may interact with other medication (for example, selegiline, antihistamines, H<sub>2</sub> antagonists, antipsychotics and sedatives).
- 1.8.2.3 Care should be taken to identify and manage restless legs syndrome (RLS) and rapid eye movement (REM) sleep behaviour disorder in people with PD and sleep disturbance.
- 1.8.2.4 People with PD who have sudden onset of sleep should be advised not to drive and to consider any occupational hazards. Attempts should be made to adjust their medication to reduce its occurrence.

### Daytime hypersomnolence

- 1.8.2.5 Modafinil may be considered for daytime hypersomnolence in people with PD.

### Nocturnal akinesia

- 1.8.2.6 Modified-release levodopa preparations may be used for nocturnal akinesia in people with PD.

### 1.8.3 Falls

1.8.3.1 For all people with PD at risk of falling, please refer to [Falls: assessment and prevention of falls in older people](#) NICE clinical guideline 21.

### 1.8.4 Autonomic disturbance

1.8.4.1 People with PD should be treated appropriately for the following autonomic disturbances<sup>[9]</sup>:

- urinary dysfunction
- weight loss
- dysphagia
- constipation
- erectile dysfunction
- orthostatic hypotension
- excessive sweating
- sialorrhoea.

## 1.9 Other key interventions

### 1.9.1 Specialist nurse interventions

1.9.1.1 People with PD should have regular access to the following:

- clinical monitoring and medication adjustment
- a continuing point of contact for support, including home visits, when appropriate
- a reliable source of information about clinical and social matters of concern to people with PD and their carers

which may be provided by a Parkinson's disease nurse specialist.

## 1.9.2 Physiotherapy

1.9.2.1 Physiotherapy should be available for people with PD. Particular consideration should be given to:

- gait re-education, improvement of balance and flexibility
- enhancement of aerobic capacity
- improvement of movement initiation
- improvement of functional independence, including mobility and activities of daily living
- provision of advice regarding safety in the home environment.

1.9.2.2 The Alexander Technique may be offered to benefit people with PD by helping them to make lifestyle adjustments that affect both the physical nature of the condition and the person's attitudes to having PD.

## 1.9.3 Occupational therapy

1.9.3.1 Occupational therapy should be available for people with PD. Particular consideration should be given to:

- maintenance of work and family roles, home care and leisure activities
- improvement and maintenance of transfers and mobility
- improvement of personal self-care activities, such as eating, drinking, washing and dressing
- environmental issues to improve safety and motor function
- cognitive assessment and appropriate intervention.

## 1.9.4 Speech and language therapy

1.9.4.1 Speech and language therapy should be available for people with PD. Particular consideration should be given to:

- improvement of vocal loudness and pitch range, including speech therapy programmes such as Lee Silverman Voice Treatment (LSVT)
- teaching strategies to optimise speech intelligibility
- ensuring an effective means of communication is maintained throughout the course of the disease, including use of assistive technologies
- review and management to support safety and efficiency of swallowing and to minimise the risk of aspiration.

## 1.10 *Palliative care in Parkinson's disease*

1.10.1.1 Palliative care requirements of people with PD should be considered throughout all phases of the disease.

1.10.1.2 People with PD and their carers should be given the opportunity to discuss end-of-life issues with appropriate healthcare professionals.

---

<sup>[4]</sup> The Guideline Development Group considered that people with suspected mild PD should be seen within 6 weeks, but new referrals in later disease with more complex problems require an appointment within 2 weeks.

<sup>[5]</sup> The Guideline Development Group considered that people diagnosed with PD should be seen at regular intervals of 6–12 months to review their diagnosis.

<sup>[6]</sup> Full details of the restrictions on pergolide use and monitoring are available in the 'Summary of product characteristics'.

<sup>[7]</sup> Trade name Stalevo (Orion)

<sup>[8]</sup> GPi deep brain stimulation is rarely performed for PD in the UK at present, though it is sometimes undertaken when STN deep brain stimulation is not possible.

<sup>[9]</sup> Please refer to the [full Parkinson's disease guideline](#) for additional information.

## 2 Notes on the scope of the guidance

All NICE guidelines are developed in accordance with a scope document that defines what the guideline will and will not cover. The scope of this guideline was established, after a period of consultation, at the start of the guideline development process.

This guideline sets out best practice guidance for the diagnosis and management of PD in the NHS in England and Wales. Guidance covers primary, secondary and tertiary healthcare settings. It applies to men and women older than 20 years of age, with a diagnosis of Parkinson's disease or parkinsonism. The guidance on treatment and management is aimed at people with idiopathic Parkinson's disease only. The following areas are covered in this guideline:

- diagnosis and monitoring
- communication and education
- pharmacotherapy (prevention of progression)
- pharmacotherapy (functional disability in early disease)
- adjuvant pharmacotherapy (functional disability in late disease)
- non-pharmacological management
- neuropsychiatric conditions
- palliative care.

This guideline does not cover other therapies that do not form common clinical management (such as fetal cell transplantation; stem cells; genes that code proteins responsible for producing dopamine; drugs that block the action of glutamate; glial cell-derived neurotrophic factor [GDNF]; and viral transfection). In addition, comorbidities in Parkinson's disease are not addressed (except where treatment differs from treatment of these comorbidities in patients without Parkinson's disease). Finally, generic health problems where the care for people with Parkinson's disease does not differ to that of the general population (such as constipation) are not addressed.

### 3 Implementation in the NHS

The Healthcare Commission will assess the performance of NHS organisations in meeting core and developmental standards set by the Department of Health in 'Standards for better health' issued in July 2004.

Implementation of clinical guidelines forms part of the developmental standard D2. Core standard C5 says that national agreed guidance should be taken into account when NHS organisations are planning and delivering care.

This guideline is supported by the following [implementation tools](#).

- A slide set – key messages for local discussion.
- Costing tools:
  - a national costing report, which estimates the overall resource impact associated with implementation
  - a local costing template; a simple spreadsheet that can be used to estimate the local cost of implementation.
- Implementation advice – practical suggestions on how to address potential barriers to implementation.

Suggested audit criteria based on the key priorities for implementation are listed in [appendix D](#) and can be used to audit practice locally.

## 4 Research recommendations

The Guideline Development Group has made the following recommendations for research on the basis of its review of the evidence. The Group regards these recommendations as the most important research areas to improve NICE guidance and patient care in the future. The Guideline Development Group's full set of research recommendations is detailed in the [full guideline](#).

### 4.1 *Neuroprotection*

Do any of the agents with preclinical neuroprotective properties in PD models have any clinically worthwhile protective effects in PD?

#### **Why this is important**

At present there is no agent that slows down the progression of PD. Patients want such a 'cure' for their condition. The NHS requires neuroprotectants to reduce the burden of disability caused by PD, thereby reducing the direct and indirect costs of caring for an increasing number of people with the condition.

A systematic trial programme examining these agents is ongoing in the USA (NET-PD). Agents are being screened in small 'futility studies' using historical control data for decline in total UPDRS scores. The first futility study showed that both minocycline and GPi 1485 significantly delay decline in total UPDRS by more than 30% (K Kiebertz, personal communication).

The recent rasagiline delayed-start design trial versus placebo raised the possibility that this may be a useful trial design to examine neuroprotection. Support for further surgical approaches to neuroprotection in PD should be considered.

### 4.2 *Dementia*

Which people with PD and dementia benefit from cholinesterase inhibitors and/or memantine, and is the use of these agents cost effective?

#### **Why this is important**

A recent systematic review indicated that 24–31% of patients with PD have dementia, and that 3–4% of the dementia in the general population is due to Parkinson's disease dementia (PDD). The

estimated prevalence of PDD in the general population aged 65 years and older is 0.2–0.5%. PDD is associated with increased mortality, care-giver stress and nursing home admission.

A large randomised controlled trial (RCT) of rivastigmine in PDD showed improvements in primary and secondary end points, but the clinical significance of these benefits is uncertain. It is likely that the modest mean improvements reflect heterogeneity of response, with some patients responding far better than others; this is supported by expert opinion via open-label prescribing. In addition, health economics analyses have not been performed in trials of cholinesterase inhibitors in PDD using disease-specific models.

Identifying responsive subgroups of patients with PDD with demonstrable cost effectiveness would focus effective targeting of cholinesterase inhibitors and/or memantine. The process of identifying these patients would also lead to the development of protocols for prescribing and assessment, together with robust guidelines regarding whether drug usage is maintained or discontinued.

### 4.3 *Depression*

Is treating mild to moderate depression in PD with an antidepressant cost effective?

#### **Why this is important**

Cross-sectional studies have shown that depression affects around 40% of patients with PD and has a major impact on quality of life. In most cases, depression is mild to moderate in severity and is often missed by the clinician caring for the patient.

The GDG recommends a study that would screen secondary care Parkinson's disease clinic populations for mild to moderate depression. Participants would then be treated with any SSRI class antidepressant or no such treatment in an open-label fashion. This would be a large-scale pragmatic trial.

If screening for and treating mild to moderate depression is cost effective, this would add to the evidence base for the management of depression in Parkinson's disease and may have considerable impact on the next update of this guideline.

## 4.4 *Supportive therapies*

### 4.4.1 **Physiotherapy**

Is physiotherapy in PD cost effective?

#### **Why this is important**

The evidence to support the use of physiotherapy in Parkinson's disease is limited and yet patients feel that it is effective. Many patients are referred for such therapy in the NHS with little idea of its value or whether it has any long-term benefits. In contrast, many other patients cannot access such therapy due to limited provision of service.

The GDG recommends a pragmatic trial should be performed in units that already have access to physiotherapy services. This is likely to be in the elderly care setting because neurologists have limited access to such treatments.

If physiotherapy is cost effective then the provision of service needs to be increased.

Future trials will then need to examine which components of physiotherapy are effective and whether it is effective in the earlier stages of the disease.

### 4.4.2 **Occupational therapy**

Is occupational therapy in PD cost effective?

#### **Why this is important**

The evidence to support the use of occupational therapy in PD is limited and yet patients feel that it is effective. Many patients are referred for such therapy in the NHS with little idea of its value or whether it has any long-term benefits. In contrast, many other patients cannot access such therapy due to limited provision of service.

The GDG recommends a pragmatic trial should be performed in units that already have access to occupational therapy services. This is likely to be in the elderly care setting because neurologists have poor access to such treatments.

If occupational therapy is cost effective then the provision of service needs to be increased.

Future trials will then need to examine what components of occupational therapy are effective and whether it is effective in the earlier stages of the disease.

### 4.4.3 Speech and language therapy

Is NHS speech and language therapy in PD cost effective?

#### Why this is important

The evidence to support the use of speech and language therapy in PD is limited and yet patients feel that it is effective. The provision of this service in the NHS is patchy with some patients not receiving speech and language therapy when it may be appropriate.

The GDG recommends a trial that is preceded by survey work to identify current and best practice speech and language therapy for PD in the UK. Similar work has already been performed for physiotherapy and occupational therapy to prepare for analogous trials.

In this pragmatic trial, standard NHS speech and language therapy would be compared with no treatment. Whilst most PD units have access to some speech and language therapy service, this may be insufficient for trial purposes so an NHS subvention would be required.

If speech and language therapy is cost effective, then the provision of service needs to be increased.

## 4.5 Diagnostic investigations

Which diagnostic investigations for PD and potential biomarkers of its progression are clinically useful and cost effective?

#### Why this is important

The diagnosis of PD remains clinical. <sup>123</sup>I-FP-CIT SPECT may be of additional help in a small proportion of clinically uncertain cases. The diagnostic error rate on presentation may be as high as 10% in expert hands, which may lead to inappropriate therapy and distress following revision of the diagnosis.

A systematic approach would expedite the evaluation of existing and new diagnostic techniques.

The considerable debate surrounding biomarkers to measure the progression of PD has highlighted the need for further studies in this area. More work on existing techniques (for example, SPECT and PET) is required and the development of new potential markers of progression is urgently required.

## 5 Other versions of this guideline

The National Institute for Health and Clinical Excellence commissioned the development of this guidance from the National Collaborating Centre for Chronic Conditions. The Centre established a Guideline Development Group, which reviewed the evidence and developed the recommendations. The members of the Guideline Development Group are listed in [appendix B](#). Information about the independent Guideline Review Panel is given in [appendix C](#).

There is more information about [how NICE clinical guidelines are developed](#) on the NICE website. A booklet, 'How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS' is [available](#).

### 5.1 *Full guideline*

The full guideline, [Parkinson's disease: diagnosis and management in primary and secondary care](#), is published by the National Collaborating Centre for Chronic Conditions.

### 5.2 *Information for the public*

NICE has produced [information for the public](#) explaining this guideline.

We encourage NHS and voluntary sector organisations to use text from this information in their own materials.

## 6 Related NICE guidance

Dementia. [NICE clinical guideline 42](#). (2006)

Depression: management of depression in primary and secondary care. NICE clinical guideline 23 (2004). [Replaced by [NICE clinical guideline 90](#)]

Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition. [NICE clinical guideline 32](#) (2006).

Falls: The assessment and prevention of falls in older people. [NICE clinical guideline 21](#) (2004).

Deep brain stimulation for Parkinson's disease. [NICE interventional procedure guidance 19](#) (2003).

Alzheimer's disease - donepezil, rivastigmine and galantamine. NICE technology appraisal 19 (2001). [Replaced by [NICE technology appraisal 111](#)]

## 7 Review date

The process of reviewing the evidence is expected to begin 4 years after the date of issue of this guideline. Reviewing may begin before this if significant evidence that affects the guideline recommendations is identified. The updated guideline will be available within 2 years of the start of the review process.

## Appendix A: Grading scheme

The recommendations in this guideline were graded according to the quality of the evidence they were based on. The gradings are available in the [full guideline](#) and are not shown in this web version.

## **Appendix B: The Guideline Development Group**

**Professor David Anderson**

Consultant Psychiatrist, Mossley Hill Hospital, Liverpool

**Ms Angela Birleson**

Advanced Practitioner in Occupational Therapy, Occupational Therapy, Clinical Support Services, South Tees Hospitals NHS Trust

**Dr David Burn**

Consultant Neurologist, Newcastle General Hospital, Newcastle-upon-Tyne

**Dr Carl Clarke**

Clinical Advisor, City Hospital and University of Birmingham

**Ms Bernadette Ford**

Information Scientist, NCC-CC

**Mr Michael Godfrey**

Patient Representative, Parkinson's Disease Society

**Ms Jacqui Handley**

Parkinson's Disease Nurse Specialist, Dorset County Hospital, Dorchester

**Dr John Hindle**

Consultant Physician, Care of the Elderly, North West Wales NHS Trust, Bangor

**Professor Brian Hurwitz**

General Practitioner, King's College London

**Professor Andrew Lees**

Professor of Neurology, Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London

**Dr Alastair Mason**

GDG Chair, NCC-CC

**Dr Doug MacMahon**

Consultant Physician (with special responsibility for the elderly), Royal Cornwall Hospitals NHS Trust

**Mr David McNiven**

Policy and Campaigns Manager, Parkinson's Disease Society

**Mr Robert Meadowcroft**

Director of Policy, Campaigns and Information, Parkinson's Disease Society

**Ms Debbie Nicholl**

Health Economist, NCC-CC

**Ms Jill Parnham**

Senior Research Fellow, NCC-CC

**Ms Bhanu Ramaswamy**

Consultant Physiotherapist, Walton Hospital, Chesterfield

**Ms Tara Sullivan**

Research Fellow and Project Manager, NCC-CC

**Ms Nicole Wilson**

Project Manager, NCC-CC

**Julia Johnson**

Speech and Language Therapist, Kings College Hospital, London

**TRK Varma**

Consultant Neurosurgeon, Walton Centre for Neurology and Neurosurgery, Liverpool

**Ana Aragon**

Specialist Occupational Therapist for Parkinson's Disease, Bath and North East Somerset Primary Care Trust

**Ira Leroi**

Consultant in Old Age Psychiatry, Manchester Mental Health and Social Care Trust

**Karen Durrant**

Superintendent Physiotherapist, Walton Hospital, Chesterfield

**David Stewart**

Consultant Physician, Medicine for the Elderly, Mansion House Unit, Victoria Infirmary, Glasgow

## **Appendix C: The Guideline Review Panel**

The Guideline Review Panel is an independent panel that oversees the development of the guideline and takes responsibility for monitoring its quality. The Panel includes experts on guideline methodology, health professionals and people with experience of the issues affecting patients and carers. The members of the Guideline Review Panel were as follows.

**Dr Peter Rutherford (Chair)**

Senior Lecturer in Nephrology, University of Wales College of Medicine

**Dame Helena Shovelton**

Chief Executive, British Lung Foundation

**Dr Rob Higgins**

Consultant in Renal and General Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry

**Dr John Young**

Medical Director, Merck Sharp & Dohme (MSD)

## Appendix D: Technical detail on the criteria for audit

The GDG recommends that healthcare-commissioning organisations survey the views of people with PD regarding patient views. This approach would enable the organisations to investigate the totality of the services and identify particular areas in need of development using a patient-centred approach.

Criterion	Exception	Definition of terms
1. 100% of people with suspected Parkinson's disease are seen within 6 weeks of GP referral.	None	None
2. 100% of people with Parkinson's disease are reviewed at 6- to 12-month intervals.	None	None
3. 0% of people with suspected PD are offered acute levodopa and/or apomorphine challenge tests for the differential diagnosis of parkinsonian syndromes.	None	None
4. 100% of people with Parkinson's disease have access to a Parkinson's disease nurse specialist or other professional capable of providing: <ul style="list-style-type: none"> <li>• clinical monitoring and medication adjustment</li> <li>• a continuing point of contact for support, including home visits, when appropriate</li> <li>• a reliable source of information about clinical and social matters of concern to people with PD and their carers.</li> </ul>	None	None
5. For 100% of people with Parkinson's disease, at diagnosis and each regular review, physiotherapy is available and appropriate referral is activated. This is recorded in the patient's notes.	None	None
6. For 100% of people with Parkinson's disease, at diagnosis and each regular review, occupational therapy is available and appropriate referral is activated. This is recorded in the patient's notes.	None	None
7. For 100% of people with Parkinson's disease, at diagnosis and each regular review, speech and language therapy is available and appropriate referral is activated. This is recorded in the patient's notes.	None	None

8. 100% of people with PD should be given opportunities to discuss and ask questions about their palliative care requirements with appropriate healthcare professionals.	None	None
--	------	------

## Appendix E: Algorithm

The [full guideline](#) contains the algorithm.

## About this guideline

NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.

The guideline was developed by the National Collaborating Centre for Chronic Conditions. The Collaborating Centre worked with a group of healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, who reviewed the evidence and drafted the recommendations. The recommendations were finalised after public consultation.

The methods and processes for developing NICE clinical guidelines are described in [The guidelines manual](#).

We have produced [information for the public](#) explaining this guideline. Tools to help you put the guideline into practice and information about the evidence it is based on are also [available](#).

### Changes after publication

March 2014: minor maintenance

November 2013: minor maintenance

March 2012: minor maintenance

### Your responsibility

This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

## Copyright

© National Institute for Health and Clinical Excellence 2006. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

## Contact NICE

National Institute for Health and Clinical Excellence  
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

[www.nice.org.uk](http://www.nice.org.uk)

[nice@nice.org.uk](mailto:nice@nice.org.uk)

0845 003 7780